EUVIMEDSkopri EUVIMED
KohortenstudieOpen access · CC BY-NC 4.0

Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population‐Based Cohort Study

Vilhelm Hjälte iD, Pär Myrelid iD, Henrik Hjortswang, Martin Rejler, SWIBREG Study Group, Jonas F Ludvigsson iD, Anders Forss iD, Marcus Bendtsen, Ola Olén, Åsa H Everhov iD, Michael Eberhardson

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70069 ↗

At a glance

Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Vilhelm Hjälte and 10 co-authors. Institution: Department of Gastroenterology and Hepatology, University Hospital, Linköping, Sweden. Major MEDLINE topics: Crohn Disease, Adrenal Cortex Hormones, Cecum, Ileum. Cited 1 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Region Östergötland.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

The corticosteroid‐sparing effects of ileocaecal resection have not been thoroughly investigated in a population‐based cohort.

Aim

To investigate systemic corticosteroid use before and after primary ileocaecal resection in patients with Crohn's disease.

Methods

Through nationwide registries, we identified 1565 patients with Crohn's disease undergoing primary ileocaecal resection in Sweden 2006–2019. We stratified patients according to mean annual systemic corticosteroid (prednisolone equivalents) use in the last 5 years before surgery and compared Crohn's disease treatment after surgery.

Results

Some 19% (290/1565) of the patients had a mean annual corticosteroid use of ≥ 1000 mg up to 5 years pre‐operatively, of whom 33% (97/290) had ≥ 2000 mg. Mean annual pre‐operative CS use did not decrease during the study period ( p = 0.35). Compared with patients with < 1000 mg/year pre‐operative steroid use, patients with ≥ 1000 mg/year had more frequent previous bowel surgery (10% vs. 16%), exposure to biologics (29% vs. 38%), and immunomodulators (56% vs. 83%). Patients with a pre‐operative mean annual corticosteroid use of ≥ 1000 mg had a mean annual reduction in corticosteroid use of 1354 mg after ileocaecal resection (1847 mg pre‐operative versus 493 mg post‐operative). During follow‐up (median 6.8 years), exposure to biologics was similar among patients with different levels of pre‐operative corticosteroid use.

Conclusion

Our results suggest a significant corticosteroid‐sparing effect of ileocaecal resection in Crohn's disease patients with high pre‐operative use, indicating a beneficial outcome of earlier surgical intervention. Despite increasing use of biologics, pre‐operative corticosteroid use was consistent over the study period.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseAdrenal Cortex HormonesCecumIleumHumansMaleFemaleSwedenAdultMiddle AgedCohort StudiesRegistriesYoung AdultAged

Author keywords

Crohn's diseasebowel surgerycorticosteroidsileocaecal resection

Substances

Adrenal Cortex Hormones

Authors and institutions

  • Department of Gastroenterology and Hepatology, University Hospital, Linköping, Sweden.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Department of Surgery and Department of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
  • Jönköping Academy for Improvement of Health and Welfare, Jönköping University, Jönköping, Sweden.
  • Futurum-Academy for Healthcare, Region Jönköping County, Jönköping, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

ORCID profiles: Vilhelm Hjälte, Pär Myrelid, Jonas F Ludvigsson, Anders Forss, Åsa H Everhov

Funding

  • Region Östergötland

Cite

APA

Hjälte, V., Myrelid, P., Hjortswang, H., Rejler, M., SWIBREG Study Group, Ludvigsson, J. F., Forss, A., Bendtsen, M., Olén, O., Everhov, Å. H., & Eberhardson, M. (2025). Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population‐Based Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70069

Vancouver

Hjälte V, Myrelid P, Hjortswang H, Rejler M, SWIBREG Study Group, Ludvigsson JF, et al. Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population‐Based Cohort Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70069

BibTeX
@article{Hjlte2025,
  author = {Hjälte, Vilhelm and Myrelid, Pär and Hjortswang, Henrik and Rejler, Martin and SWIBREG Study Group, SWIBREG Study Group and Ludvigsson, Jonas F and Forss, Anders and Bendtsen, Marcus and Olén, Ola and Everhov, Åsa H and Eberhardson, Michael},
  title = {Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population‐Based Cohort Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70069}
}
Start for free →